XML 211 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Income Per Share and Stockholders' Equity
 9 Months Ended
Sep. 30, 2025
Earnings Per Share And Stockholders Equity [Abstract]  
Income Per Share and Stockholders' Equity Income Per Share and Stockholders’ Equity
The calculations of basic and diluted income per share attributable to CBRE Group, Inc. stockholders are as follows (dollars in millions, except share and per share data):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
Basic Income Per Share
Net income attributable to CBRE Group, Inc. stockholders$363 $225 $741 $481 
Weighted average shares outstanding for basic income per share297,557,891 306,253,811 298,589,340 306,269,264 
Basic income per share attributable to CBRE Group, Inc. stockholders$1.22 $0.73 $2.48 $1.57 
Diluted Income Per Share
Net income attributable to CBRE Group, Inc. stockholders$363 $225 $741 $481 
Weighted average shares outstanding for basic income per share297,557,891 306,253,811 298,589,340 306,269,264 
Dilutive effect of contingently issuable shares2,699,439 2,051,202 2,461,001 2,011,847 
Weighted average shares outstanding for diluted income per share300,257,330 308,305,013 301,050,341 308,281,111 
Diluted income per share attributable to CBRE Group, Inc. stockholders$1.21 $0.73 $2.46 $1.56 
No shares were excluded from the computation of diluted income per share for the three months ended September 30, 2025. For the nine months ended September 30, 2025, 331,034 of contingently issuable shares were excluded from the computation of diluted income per share because their inclusion would have had an anti-dilutive effect.
For the three and nine months ended September 30, 2024, 5,875 and 238,815, respectively, of contingently issuable shares were excluded from the computation of diluted income per share because their inclusion would have had an anti-dilutive effect.
On November 21, 2024, our board of directors authorized an additional $5.0 billion to our existing $4.0 billion share repurchase program (as amended, the 2024 program) bringing the total authorized amount under the 2024 program to a total of $9.0 billion as of September 30, 2025. The board also extended the term of the 2024 program through December 31, 2029.
We did not repurchase any shares of our common stock during the three months ended September 30, 2025 under the 2024 program. During the nine months ended September 30, 2025, we repurchased 5,185,163 shares of our common stock with an average price of $127.82 per share for an aggregate of $663 million under the 2024 program. As of September 30, 2025, we had approximately $5.2 billion of capacity remaining under the 2024 program.
During the three months ended September 30, 2024, we repurchased 567,209 shares of our common stock with an average price of $109.20 per share for an aggregate of $62 million under the 2024 program. During the nine months ended September 30, 2024, we repurchased 1,121,950 shares of our common stock with an average price of $98.35 per share for an aggregate of $110 million under the 2024 program.